# Grok 4.7 / inf-k01

Original final answer, shared by both scoring rounds.

A well-controlled GWAS association at this locus establishes only that the tested haplotype region is associated with the trait. It does not identify a causal variant or an effector gene. The lead noncoding SNP near G is a statistical tag; linked variants spanning G and H remain interchangeable candidates, and neither gene is established as the mediator.

## Evidence-to-inference chain

**Evidence (E1 only).** A well-controlled GWAS reports a lead noncoding SNP near gene G. Several variants in linkage with that SNP span G and H. No linkage-disequilibrium (LD) metrics, conditional statistics, fine-mapping posterior probabilities, colocalization results, annotations, or functional data are supplied. No validation results exist beyond this packet; none should be inferred.

**Inference.** The association localizes risk to a correlated set of alleles, not to one base or one gene. Because the lead SNP is noncoding, a protein-altering mechanism in G is not supported by the lead marker itself. Regulation of G, regulation of H, regulation of an unlisted gene, or an effect that does not act through either gene are all compatible with E1.

**Conclusion.** Stop at “associated locus containing G and H.” Any claim that the lead SNP is causal, or that G rather than H is the effector gene, exceeds the evidence.

## What each step can and cannot establish

**1. GWAS association.**  
Can establish: under the study’s design and controls, trait risk differs by genotype at the locus; the lead SNP is the strongest single-marker association among those tested, not a proven causal site.  
Cannot establish: which variant is causal; whether one or several variants contribute; which gene, if any, mediates the effect; the cell type or direction of effect. Controls reduce confounding and technical artifact; they do not convert a regional association into a mechanism. Winner’s curse and incomplete variant coverage can also make the lead SNP a poor proxy for the true signal.

**2. Linkage, meaning LD here—not pedigree linkage.**  
Classical linkage in families maps a broad recombinant interval. GWAS instead uses population LD: variants inherited together because recombination has not fully separated them.  
Can establish: the signal is carried by a haplotype. Variants spanning G and H may be statistically redundant with the lead SNP, so proximity of the lead SNP to G is not gene assignment.  
Cannot establish: causality of any one linked variant. A noncoding tag near G can be in LD with a coding or regulatory variant affecting H, or with a regulatory element that contacts a more distant gene. LD spread is an uncertainty, not a shortlist of two genes.

**3. Fine mapping.**  
This step is not available in E1; it would require genotypes or summary statistics, an LD reference matched to the study population, and a stated model.  
Can establish, if done: a credible set of variants that jointly have high posterior probability of including the causal variant(s) under explicit assumptions (single causal variant, correct LD, no untyped causal allele). Conditional analysis can show whether one signal remains after accounting for the lead SNP.  
Cannot establish: biological causality. A small credible set can still contain variants that only tag an untyped causal allele. Misspecified ancestry, multiple causal variants, low power, or synthetic/reference LD that does not match the GWAS sample can put the wrong variants in the set. Fine mapping also does not name the effector gene: a credible noncoding SNP may regulate G, H, both, or neither.

**4. Colocalization.**  
Not supplied. It would compare the GWAS signal with a molecular QTL (expression, splicing, protein, chromatin) in a relevant tissue.  
Can establish: statistical support that the trait association and a molecular association share a causal variant, which nominates a gene–trait hypothesis (for example, an eQTL for G but not H).  
Cannot establish: that the shared variant causes disease, or that the QTL gene is the effector. Distinct causal variants in LD can look colocalized; multiple causal variants can look non-colocalized; the wrong tissue, cell state, or developmental time can miss the true QTL; horizontal pleiotropy can link a gene to the trait without that gene mediating this locus. A positive colocalization is a prioritization, not a causal proof. Absence of colocalization does not exonerate G or H.

**5. Functional perturbation.**  
Not supplied. Useful designs, all proposed rather than performed, separate variant function from gene function.  
- Variant-level: edit or reporter-test credible-set alleles versus matched controls, reading regulatory activity, chromatin contact, or a disease-relevant cellular phenotype.  
- Gene-level: perturb G and H separately (CRISPRi/a or knockout) in the same system and ask whether the phenotype matches the direction predicted by the risk allele.  
Can establish: that a nominated allele changes a measured function, and that altering G or H changes a measured phenotype, in that assay.  
Cannot establish, by itself: in vivo disease causality, completeness of the gene set, or that an assay phenotype is the pathogenic mechanism. An active enhancer near G can control H. A gene that scores in a viability assay may be irrelevant to the GWAS trait. Base-editing and off-target effects, non-physiological expression, and wrong cell type are failure modes.

## Relationship among the steps

Association and LD define the unresolved region. Fine mapping shrinks the variant set only under statistical assumptions. Colocalization links that set to a molecular trait and thereby nominates an effector gene. Perturbation tests variant and gene necessity or sufficiency in a chosen system. Each step constrains the next; none substitutes for the later ones. Skipping from the lead SNP to “G is the causal gene” collapses four different claims into one unsupported claim.

## Alternatives still open on E1

- The causal variant is not the lead SNP but another variant in the same LD span, including one nearer H.  
- More than one causal variant exists, so conditioning on the lead SNP would leave residual signal.  
- The effector is G, H, both, a gene outside the span contacted by the element, or a noncoding RNA.  
- The locus is associated but the biological route is context-specific and invisible in adult bulk expression of G or H.  
- The lead association is real, but population structure or phenotype definition still limits transportability; “well-controlled” is accepted here as given, not re-estimated.

## What would change the recommendation

Move beyond “associated locus” only if new evidence arrives. A population-matched 95% credible set that excludes most variants spanning one gene would narrow variant candidates, not prove them. Colocalization of that set with a QTL for one gene in a disease-relevant cell type would nominate that gene over the other, still short of proof. Allele-specific editing that recreates the risk-allele molecular effect, plus selective perturbation of the nominated gene that copies that effect, would support a causal variant–effector pair in that model. Contradiction among those results—for example, fine mapping favoring a variant near H while only G perturbation matters—should block a single-gene conclusion rather than be averaged away.

## Unreported parameters and limits

LD \(r^2\), allele frequencies, sample size, ancestry match, number of independent signals, window boundaries, and whether G or H promoters contact the lead SNP are unreported. No experiment has been run. The operational next action is therefore methodological, not a gene call: obtain the summary statistics and a matched LD panel, perform conditional analysis and fine mapping, then test colocalization before any perturbation. Until those data exist, G and H are positional candidates only, and the lead noncoding SNP is a marker for the haplotype, not a demonstrated causal variant.
